Rise Therapeutics LLC
6
3
3
1
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 1 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
Role: lead
R-3750 in Patients With Mild to Moderate Ulcerative Colitis
Role: lead
R-5280 in Newly Diagnosed Patients With Type 1 Diabetes
Role: lead
R-2487 in Patients With Rheumatoid Arthritis
Role: lead
R-2487 in Patients With Sjogren's Syndrome (SS)
Role: lead
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Role: lead
All 6 trials loaded